Awarded Project: "CMV-vectored vaccine approaches to induce protective antibodies to HIV-1 Env"

CMV-vectored Vaccine Approaches to Induce Protective Antibodies to HIV-1 Env

Dr. Peter Barry recently received a two year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to study “CMV-vectored vaccine approaches to induce protective antibodies to HIV-1 Env” (R21AI134618).  This proposal is an exploratory investigation into approaches that will (1) promote antibody responses to rhesus cytomegalovirus (RhCMV)-vectored SIV vaccines in the face of pre-existing RhCMV immunity, and (2) increase SIV antigen expression. This application develops two distinctive approaches for inducing anti-Env antibodies and protective antibody responses, which when combined with a superior CTL vaccine modality (CMV-based vectors), may finally meet the challenge of a balanced optimized HIV-1 vaccine. 

NIAID Logo

 

 

 

Tags